Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

ABSTRACT: eCLIP-seq was performed using CAL-1 cells treated with control (DMSO) or venetoclax+azacitidine (VenAza) for 6 hours to identify KHSRP-interacting RNAs

ORGANISM(S): Homo sapiens

PROVIDER: GSE301866 | GEO | 2026/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

Project description:KHSRP was knocked down in CAL-1 cells by CRISPR interference, then RNA-seq was performed in control and KHSRP knockdown cells to assess differentially expressed genes.

2025-10-28 | GSE301870 | GEO

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

Project description:Human PDX cells were enriched from mice treated with vehicle control or venetoclax + azacitidine

2026-07-07 | GSE301872 | GEO

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

Project description:Acute myeloid leukemia (AML) remains highly prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in AML cells treated with multiple agents. KHSRP was the top hit, whose depletion sensitized AML cells to therapy and substantially prolonged survival in treated AML-bearing mice. Profiling in vivo residual disease after therapy identified downregulation of the vitamin C and uric acid transporter SLC23A1 as a resistance mechanism. KHSRP depletion restored SLC23A1 through a previously unrecognized function by preventing ZC3H4-mediated nuclear mRNA degradation. KHSRP depletion therefore enhanced the synergistic cytotoxicity of vitamin C and uric acid, particularly in therapy-persistent leukemia cells. Re-expression of TET2 overrode the chemosensitizing effect of KHSRP depletion in TET2-mutant leukemia, suggesting that KHSRP phenotypes were linked to vitamin C and uric acid-mediated TET activation. These findings nominate targeting KHSRP to enhance treatment efficacy and selectively eradicate residual AML.

2026-07-10 | GSE337663 | GEO

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

| PRJNA1287681 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

| PRJNA1287679 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

| PRJNA1490549 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

| PRJNA1287680 | ENA

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056183 | Pride

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 6h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056189 | Pride

Effect of KHSRP acetylation on gene expression in LNCaP cells

Project description:We established LNCaP cells in wihch KHSRP was knocked down along with LNCaP cells with silenced KHSRP and re-introduced HA-tagged KHSRP-WT/K205R.RNA-seq was carried out in the stable LNCaP cell lines to determine the underlying mechanism of KHSRP acetylation in PCa tumorigenesis. We then performed gene expression profiling analysis using data obtained from RNA-seq of 4 different cells.

2024-05-27 | GSE206486 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data